IRhythm (NASDAQ:IRTC) will collaborate with Alphabet’s Verily to develop solutions to improve the screening, diagnosis and management of atrial fibrillation (AF) patients.
The partnership will leverage IRTC’s knowhow in AI-based arrhythmia diagnosis with Verily’s advanced health data analytics technologies.
Under the terms of the agreement, IRTC will pay Verily $5M upfront and up to $12.75M in development and regulatory milestones.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.